<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4978">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03042130</url>
  </required_header>
  <id_info>
    <org_study_id>TASMC-16-HO-512-CTIL</org_study_id>
    <nct_id>NCT03042130</nct_id>
  </id_info>
  <brief_title>Treatment With IV Iron in Hospitalized Patients With Severe Heart Failure But Without Iron Deficiency</brief_title>
  <official_title>Treatment With IV Iron in Hospitalized Patients With Severe Heart Failure But Without Iron Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tel-Aviv Sourasky Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tel-Aviv Sourasky Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with congestive heart failure, grade 3-4, in addition to the standard care, will be
      randomized 1:1. The study group will receive 2 doses of IV iron (Iron carboxymaltose). The
      control group will receive standard of care alone. The study will test for the effects of
      the additional IV iron on the symptoms, clinical picture and quality of life of the treated
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with congestive heart failure, grade 3-4, in addition to the standard care, will be
      randomized 1:1. The study group will receive 2 doses of IV iron (Iron carboxymaltose). The
      control group will receive standard of care alone. The study will test for the effects of
      the additional IV iron on the symptoms, clinical picture and quality of life of the treated
      patients. The parameters that will be measured will include clinical, lab, echo, and quality
      of life questionnaires.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 15, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Functioning improvement</measure>
    <time_frame>5 days after second administration</time_frame>
    <description>NYHA assesment (New York Heart Association (NYHA) Functional Classification)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life improvement</measure>
    <time_frame>5 days after second administration</time_frame>
    <description>KCCQ questionnaires</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functioning improvement</measure>
    <time_frame>1 month after second administration</time_frame>
    <description>NYHA assesment (New York Heart Association (NYHA) Functional Classification)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life improvement</measure>
    <time_frame>1 month after second administration</time_frame>
    <description>KCCQ (The Kansas City Cardiomyopathy Questionnaire)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Iron Carboxymaltose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>standard of care + double dose of IV iron ferinject
the medicine will be given twice within one week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>standard of care</description>
    <arm_group_label>Iron Carboxymaltose</arm_group_label>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron Carboxymaltose</intervention_name>
    <description>Two IV doses</description>
    <arm_group_label>Iron Carboxymaltose</arm_group_label>
    <other_name>Ferinject</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Heart failure grade 3-4

          -  Heart echo EF&lt; 40% (ejection fraction)

          -  Hb &gt; 10 mg/dL

          -  Iron&gt; 50 mic/dL

          -  Iron/ transferrin rate &gt; 20%

        Exclusion Criteria:

          -  Infection

          -  Acute ischemia

          -  Patients that didn't receive the standard of care during 3 days before
             investigational product administration

          -  Hemochromatosis

          -  Known allergy to one of the products of the investigational product.

          -  Macrocytic anemia

          -  Iron excess

          -  Pregnant women

          -  Mentally disabled patients which can't give their concent properly.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard Oster, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Physician - Internal Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nitzan Sagy, SC</last_name>
    <phone>972-36972521</phone>
    <email>nitzansa@tlvmc.gov.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Moshe Mittelman, Prof.</last_name>
    <phone>972-36973366</phone>
    <email>moshemt@tlvmc.gov.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of internal medicine A</name>
      <address>
        <city>Tel-Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>February 5, 2017</lastchanged_date>
  <firstreceived_date>January 17, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Iron</mesh_term>
    <mesh_term>Ferric Compounds</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
